H3B-6545

· Eisai Inc.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for H3B-6545, covering 2024-03-22 to 2025-10-23. Get the full timeline:

Most recent: Clinical Trial Update: Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer [Phase 1]

See pricing